We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-13.75%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
-$142M
Cap. Flow
+$82.3M
Cap. Flow %
8.03%
Top 10 Hldgs %
68.99%
Holding
83
New
24
Increased
8
Reduced
9
Closed
30

Top Buys

Rank Stock Value
1
DSGN icon
Design Therapeutics
DSGN
+$92.2M
2
TIL icon
Instil Bio
TIL
+$47.4M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$34.3M
4
DYN icon
Dyne Therapeutics
DYN
+$31M
5
BCYC
Bicycle Therapeutics
BCYC
+$20.6M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$44.2M
2
KROS icon
Keros Therapeutics
KROS
+$31.7M
3
NKTX icon
Nkarta
NKTX
+$20.1M
4
APLS
Apellis Pharmaceuticals
APLS
+$17.2M
5
RNAM
Avidity Biosciences
RNAM
+$17.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.46%
2 Financials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLTX icon
51
MoonLake Immunotherapeutics
MLTX
$1.56B
$2.04M 0.2%
200,000
– –
NUVB.WS
52
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$178K 0.02%
+66,666
New +$193K
CEREW
53
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$144K 0.01%
33,333
– –
ABCL icon
54
AbCellera Biologics
ABCL
$1.65B
– –
-300,000
Closed -$12.1M
APLS
55
DELISTED
Apellis Pharmaceuticals
APLS
– –
-300,000
Closed -$17.2M
BDTX icon
56
Black Diamond Therapeutics
BDTX
$95.1M
– –
-123,465
Closed -$3.96M
CRIS icon
57
Curis
CRIS
$9.71M
– –
-3,000
Closed -$9.83M
EPIX
58
DELISTED
ESSA Pharma
EPIX
– –
-550,000
Closed -$6.56M
EYPT icon
59
EyePoint Inc
EYPT
$999M
– –
-699,999
Closed -$4.61M
GBIO
60
DELISTED
Generation Bio
GBIO
– –
-1,700
Closed -$482K
IGMS
61
DELISTED
IGM Biosciences
IGMS
– –
-150,000
Closed -$13.2M
ITOS
62
DELISTED
iTeos Therapeutics
ITOS
– –
-100,000
Closed -$3.38M
KALV
63
DELISTED
KalVista Pharmaceuticals
KALV
– –
-490,000
Closed -$9.3M
KROS icon
64
Keros Therapeutics
KROS
$197M
– –
-450,000
Closed -$31.7M
LUNG icon
65
Pulmonx
LUNG
$52.8M
– –
-75,000
Closed -$5.18M
NRIX icon
66
Nurix Therapeutics
NRIX
$2.45B
– –
-230,297
Closed -$7.57M
OM icon
67
Outset Medical
OM
$86.4M
– –
-3,333
Closed -$2.84M
PCVX icon
68
Vaxcyte
PCVX
$7.65B
– –
-140,000
Closed -$3.72M
PLRX icon
69
Pliant Therapeutics
PLRX
$65M
– –
-76,426
Closed -$1.74M
RNAM
70
DELISTED
Avidity Biosciences
RNAM
– –
-671,454
Closed -$17.1M
STTK icon
71
Shattuck Labs
STTK
$646M
– –
-121,562
Closed -$6.37M
TGTX icon
72
TG Therapeutics
TGTX
$8.19B
– –
-850,000
Closed -$44.2M
TVTX icon
73
Travere Therapeutics
TVTX
$5.17B
– –
-61,152
Closed -$1.67M
CALT
74
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
– –
-300,000
Closed -$10.1M
CERE
75
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-100,000
Closed -$1.66M
1 2
3
4

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2021 Portfolio in Review

As of Q1 2021, Logos Global Management held 83 positions worth $1.02B, down 12% from $1.17B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Logos Global Management deployed $82.3M of net new capital in Q1 2021, opening 24 new positions and adding to 8 existing holdings. Its largest new stake was Design Therapeutics: 2,732,501 shares worth $81.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 97% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Nkarta, an estimated $20.1M trimmed.

  • Logos Global Management's largest Q1 2021 buy was Design Therapeutics: 2,732,501 shares worth $81.7M.
  • Logos Global Management added most to Dyne Therapeutics in Q1 2021, an estimated $31M increase.
  • Logos Global Management's biggest Q1 2021 reduction was Nkarta, cutting an estimated $20.1M.
  • Logos Global Management fully exited TG Therapeutics in Q1 2021, selling an estimated $44.2M.
  • Logos Global Management's ten largest holdings make up 69% of its $1.02B portfolio in Q1 2021.
  • Logos Global Management opened 24 new positions and closed 30 in Q1 2021.
  • Logos Global Management's portfolio value fell 12% quarter-over-quarter to $1.02B.

Based on Logos Global Management's 13F filing for Q1 2021, filed 17 May 2021.